Eugia gets USFDA warning letter for Unit-3 in Pashamylaram

hanuman

Active member
US-FDA.jpg


Eugia Pharma, a wholly-owned subsidiary of Hyderabad-based Aurobindo Pharma received a warning letter from the USFDA. Eugia’s facility at Pashamylaram near Hyderabad was inspected between January 22 to February 2, 2024, after which serevral observations were issued. Subsequently, the company received Official Action Indicated (OAI) status in May 2024.

This warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals.

There is no impact on the existing supplies to the US markets, however, the company will not receive approval for new products from Eugia Unit-3 until the issues are resolved.



The post appeared first on .
 
Top
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock